An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.
Adult
Antigens, CD34
/ blood
Benzylamines
Cyclams
Female
Granulocyte Colony-Stimulating Factor
/ therapeutic use
Hematopoietic Stem Cell Mobilization
/ methods
Hematopoietic Stem Cell Transplantation
/ methods
Heterocyclic Compounds
/ therapeutic use
Humans
Immunoglobulin Light-chain Amyloidosis
/ mortality
Male
Middle Aged
Retrospective Studies
Survival Analysis
Transplantation, Autologous
Treatment Outcome
amyloidosis
mobilization
plerixafor
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
11
06
2019
revised:
09
08
2019
accepted:
02
09
2019
pubmed:
1
10
2019
medline:
3
4
2020
entrez:
1
10
2019
Statut:
ppublish
Résumé
The use of granulocyte-colony stimulating factor (G-CSF) with or without chemotherapy to mobilize hematopoietic progenitor cells (HPCs) can result in significant morbidity in light chain (AL) amyloidosis patients. Plerixafor, a strong inducer and mobilizer of HPCs, can be used as an adjunct to G-CSF to improve mobilization efficiency. We describe the outcomes for combined G-CSF/plerixafor mobilized patients with AL amyloidosis. We reviewed data of 53 consecutive AL amyloidosis patients who underwent combined G-CSF/plerixafor HPC mobilization between May 2011 and October 2017 at our institution. We evaluated patients for HPC collection efficiency, perimobilization toxicity and postautologous hematopoietic cell transplantation (autoHCT) outcomes. Median CD34
Identifiants
pubmed: 31566813
doi: 10.1002/jca.21747
pmc: PMC6957224
mid: NIHMS1067053
doi:
Substances chimiques
Antigens, CD34
0
Benzylamines
0
Cyclams
0
Heterocyclic Compounds
0
Granulocyte Colony-Stimulating Factor
143011-72-7
plerixafor
S915P5499N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
686-691Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL141445
Pays : United States
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
N Engl J Med. 2007 Sep 13;357(11):1083-93
pubmed: 17855669
Leukemia. 2012 Nov;26(11):2317-25
pubmed: 22475872
Biol Blood Marrow Transplant. 2018 Apr;24(4):815-819
pubmed: 29223373
Blood. 2009 Oct 8;114(15):3147-57
pubmed: 19617578
J Clin Apher. 2002;17(1):17-20
pubmed: 11948701
Transfusion. 2005 Nov;45(11):1729-34
pubmed: 16271097
J Clin Oncol. 2012 Mar 20;30(9):989-95
pubmed: 22331953
Amyloid. 2014 Sep;21(3):149-53
pubmed: 24779777
Bone Marrow Transplant. 2012 Aug;47(8):1136-7
pubmed: 22080973
Biol Blood Marrow Transplant. 2010 May;16(5):695-700
pubmed: 20067838
Bone Marrow Transplant. 2015 Apr;50(4):610-2
pubmed: 25621807
Blood. 2009 Jun 4;113(23):5720-6
pubmed: 19363221
Biol Blood Marrow Transplant. 2014 Dec;20(12):1926-31
pubmed: 25111581
Transfusion. 1998 Nov-Dec;38(11-12):1046-50
pubmed: 9838936
Blood. 2008 Sep 1;112(5):2092-100
pubmed: 18523146
J Biol Chem. 2007 Sep 14;282(37):27354-65
pubmed: 17599916
Bone Marrow Transplant. 2014 Sep;49(9):1233
pubmed: 24933207
Transfusion. 2001 Aug;41(8):1008-13
pubmed: 11493732
J Clin Oncol. 2015 Nov 10;33(32):3741-9
pubmed: 26371138
Muscle Nerve. 2007 Oct;36(4):411-23
pubmed: 17554795
J Clin Oncol. 2011 Feb 1;29(4):e79-80
pubmed: 21060030
Br J Haematol. 2010 Sep;150(6):647-62
pubmed: 20636438
Bone Marrow Transplant. 2003 May;31(10):851-5
pubmed: 12748660
Transfusion. 2013 Jan;53(1):91-5
pubmed: 22738220